123 related articles for article (PubMed ID: 7718327)
1. Formation of cytosine arabinoside-5'-triphosphate in different cultured lymphoblastic leukaemic cells with reference to their drug sensitivity.
Köhl U; Schwabe D; Montag E; Bauer S; Mieth B; Cinatl J; Cinatl J; Rohrbach E; Mainke M; Weissflog A
Eur J Cancer; 1995; 31A(2):209-14. PubMed ID: 7718327
[TBL] [Abstract][Full Text] [Related]
2. Role of dephosphorylation in accumulation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in human lymphoblastic cell lines with reference to their drug sensitivity.
Abe I; Saito S; Hori K; Suzuki M; Sato H
Cancer Res; 1982 Jul; 42(7):2846-51. PubMed ID: 7083175
[TBL] [Abstract][Full Text] [Related]
3. Prediction of sensitivity to 1-beta-D-arabinofuranosylcytosine by the plateau level of its 5'-triphosphate in human lymphoblastic cell lines in vitro.
Abe I; Saito S; Hori K; Suzuki M; Sato H
Eur J Cancer Clin Oncol; 1983 Jul; 19(7):941-4. PubMed ID: 6576907
[TBL] [Abstract][Full Text] [Related]
4. Modulation of metabolism and cytotoxicity of cytosine arabinoside with N-(phosphon)-acetyl-L-aspartate in human leukemic blast cells and cell lines.
Noordhuis P; Kazemier KM; Kasperrs GJ; Peters GJ
Leuk Res; 1996 Feb; 20(2):127-34. PubMed ID: 8628011
[TBL] [Abstract][Full Text] [Related]
5. Pharmacology of intracellular cytosine-arabinoside-5'-triphosphate in malignant cells of pediatric patients with initial or relapsed leukemia and in normal lymphocytes.
Koehl U; Hollatz G; Rohrbach E; Visschedyk K; Cinatl J; Kornhuber B; Kreuter J; Mutschler E; Schwabe D
Cancer Chemother Pharmacol; 2007 Sep; 60(4):467-77. PubMed ID: 17171362
[TBL] [Abstract][Full Text] [Related]
6. All-trans-retinoic acid increases cytosine arabinoside cytotoxicity in HL-60 human leukemia cells in spite of decreased cellular ara-CTP accumulation.
Freund A; Rössig C; Lanvers C; Gescher A; Hohenlöchter B; Jürgens H; Boos J
Ann Oncol; 1999 Mar; 10(3):335-8. PubMed ID: 10355579
[TBL] [Abstract][Full Text] [Related]
7. Formation of cytosine arabinoside-5'-triphosphate in cultured human leukemic cell lines correlates with nucleoside transport capacity.
Tanaka M; Yoshida S
Jpn J Cancer Res; 1987 Aug; 78(8):851-7. PubMed ID: 3115933
[TBL] [Abstract][Full Text] [Related]
8. Intracellular dCTP/ara-CTP ratio and the cytotoxic effect of ara-C.
Kawasaki H; Kuwabara H; Hori H; Higashigawa M; Ohkubo T; Sakurai M
Cancer Invest; 1991; 9(4):409-13. PubMed ID: 1884247
[TBL] [Abstract][Full Text] [Related]
9. Cellular pharmacology of 1-beta-D-arabinofuranosylcytosine in human myeloid, B-lymphoid and T-lymphoid leukemic cells.
Momparler RL; Onetto-Pothier N; Bouffard DY; Momparler LF
Cancer Chemother Pharmacol; 1990; 27(2):141-6. PubMed ID: 2249330
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic and DNA methylation studies of high-dose 1-beta-D-arabinofuranosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukemia.
Avramis VI; Mecum RA; Nyce J; Steele DA; Holcenberg JS
Cancer Chemother Pharmacol; 1989; 24(4):203-10. PubMed ID: 2473850
[TBL] [Abstract][Full Text] [Related]
11. [Intracellular retention of cytarabine-triphosphate (Ara-CTP) in blasts of children with acute lymphoblastic leukemia. Correlation with clinical course parameters].
Schiller M; Hohenlöchter B; Schulze-Westhoff P; Zimmermann M; Ritter J; Jürgens H; Boos J
Klin Padiatr; 1996; 208(4):151-9. PubMed ID: 8926681
[TBL] [Abstract][Full Text] [Related]
12. Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines.
Ramilo-Torno LV; Avramis VI
Cancer Chemother Pharmacol; 1995; 35(3):191-9. PubMed ID: 7805176
[TBL] [Abstract][Full Text] [Related]
13. Efficient formation of cytosine arabinoside-5'-triphosphate in leukemic blasts of human T-cell acute lymphoblastic leukemia.
Tanaka M; Yoshida S
Leuk Res; 1989; 13(10):931-6. PubMed ID: 2586146
[TBL] [Abstract][Full Text] [Related]
14. Intracellular retention of cytosine arabinoside triphosphate in blast cells from children with acute myelogenous and lymphoblastic leukemia.
Boos J; Hohenlöchter B; Schulze-Westhoff P; Schiller M; Zimmermann M; Creutzig U; Ritter J; Jurgens H
Med Pediatr Oncol; 1996 Jun; 26(6):397-404. PubMed ID: 8614376
[TBL] [Abstract][Full Text] [Related]
15. On the interaction between cytosine arabinoside and etoposide in vivo and in vitro.
Liliemark J; Knochenhauer E; Gruber A; Pettersson B; Björkholm M; Peterson C
Eur J Haematol; 1993 Jan; 50(1):22-5. PubMed ID: 8436210
[TBL] [Abstract][Full Text] [Related]
16. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
Plunkett W; Liliemark JO; Adams TM; Nowak B; Estey E; Kantarjian H; Keating MJ
Cancer Res; 1987 Jun; 47(11):3005-11. PubMed ID: 3471322
[TBL] [Abstract][Full Text] [Related]
17. In-vitro studies on phosphorylation and dephosphorylation of cytosine arabinoside in human leukemic cells.
Muus P; Drenthe-Schonk A; Haanen C; Wessels H; Linssen P
Leuk Res; 1987; 11(4):319-25. PubMed ID: 3470578
[TBL] [Abstract][Full Text] [Related]
18. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
Gandhi V; Estey E; Du M; Keating MJ; Plunkett W
Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
[TBL] [Abstract][Full Text] [Related]
19. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule.
Seymour JF; Huang P; Plunkett W; Gandhi V
Clin Cancer Res; 1996 Apr; 2(4):653-8. PubMed ID: 9816215
[TBL] [Abstract][Full Text] [Related]
20. Calculation of individual dosage regimen of cytosine arabinoside (ara-C) based on metabolite levels in leukemic cells.
Riva-Lavieille C; Ressayre C; Barra Y; Carcassonne Y; Iliadis A
Ther Drug Monit; 1994 Aug; 16(4):375-9. PubMed ID: 7974627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]